10-Deacetyl Baccatin III
(10-DAB III)

Written by

Reviewed by

Picture of Gaurav Sood
Gaurav Sood

Partner - HimPharm

Picture of Dr B M Sood
Dr B M Sood

Chairman - HimPharm

10-DAB III

Trade Names: 10 DAB III

Category: Phytochemical

Routes of Administration: Oral, Intravenous

ATC Code: N/A

Identifiers

  • CAS Number: 32981-86-5
  • PubChem CID: 72399
  • ChemSpider ID: 65345
  • ChEBI ID: 9327
  • ChEMBL ID: CHEMBL386046

Chemical and Physical Data

  • Molecular Formula: C29H36O10
  • Molar Mass: 544.59 g/mol
  • Appearance: White crystalline powder

SMILES and InChI

  • SMILES: CC(=O)O[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C
    =C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@H]1OC(=O)C5=C
    C(=C(C=C5)O)O
  • InChI: InChI=1S/C29H36O10/c1-14(30)36-20-9-16-18
    (10-19(20)31)27(33)28(6,23(32)34-15(2)29(16,3)4)
    24(35-25(27)37-17(5)21(28)26(38-14)39-7)12-22(27
    )13-40-11-8/h10,14-15,17,21-22,24,26,31,38H,8,11
    -13H2,1-7H3/t14-,15-,17-,21-,22+,24+,26+,27+,28-/
    m0/s1

Introduction

What is 10 DAB III

10 DAB III, scientifically known as 10-Deacetyl Baccatin III, is an important component in the synthesis of anti-cancer drugs, particularly Paclitaxel and Docitaxel. It serves as a vital intermediate in the production of these chemotherapeutic agents, revolutionizing the pharmaceutical industry’s approach to cancer treatment. 

Derived from the Taxus baccata tree, 10 DAB III emerges as a sustainable alternative to the environmentally impactful extraction methods previously employed in obtaining Paclitaxel from Yew trees.

10 Deacetyl Baccatin III (10-DAB III)
Impact of 10 DAB III on Pharmaceutical, Drug, and Natural Products Industry

10 DAB III has significantly changed the cancer drug development and manufacturing. Its role as a intermediate for Paclitaxel & Docitaxel also referred to as the precursor to Paclitaxel and Docitaxel has streamlined large-scale synthesis processes, minimizing environmental degradation while meeting the escalating demand for anti-cancer medications. 

HimPharm, a leading pharmaceutical manufacturer, underscores its commitment to US Pharmacopoeia standards, ensuring the quality and purity of 10 DAB III, thus setting new benchmarks in pharmaceutical synthesis.

Understanding 10 DAB III

What is 10 DAB III?

10 DAB III, chemically represented as C29H36O10, serves as a critical intermediate in the synthesis of Paclitaxel and Docitaxel. Its molecular structure enables the esterification process, enhancing the pharmacological profile and therapeutic efficacy of the final anti-cancer drugs.

What is 10 DAB III used in?

Primarily, 10 DAB III finds extensive utilization in the pharmaceutical industry for the synthesis of Paclitaxel and Docitaxel, renowned for their anti-cancer properties. The esterification of 10 DAB III enhances the kinetics and pharmacological attributes of these medications, contributing to their effectiveness in cancer treatment.

What does it look like?

Physically, 10 DAB III appears as a crystalline solid with distinct molecular characteristics. Its crystalline structure and chemical properties facilitate its integration into pharmaceutical formulations, ensuring stability and efficacy.

Where does it come from – how is it obtained or processed?

10 DAB III is derived from the Taxus baccata tree, primarily extracted from its leaves through advanced extraction techniques. HimPharm’s stringent manufacturing protocols ensure the efficient extraction and purification of 10 DAB III, meeting pharmaceutical standards while minimizing environmental impact.

Why is it considered important?

The significance of 10 DAB III lies in its pivotal role as a precursor to Paclitaxel and Docitaxel, two essential anti-cancer drugs. Its efficient synthesis process not only addresses environmental concerns but also ensures sustainable drug production to meet the growing healthcare demands worldwide.

Where does it find use in?

In the pharmaceutical industry, 10 DAB III serves as a cornerstone in the synthesis of anti-cancer medications, addressing critical healthcare needs worldwide. Its versatile nature allows for potential applications in medicinal chemistry, paving the way for innovative drug development and therapeutic interventions.

History of 10 DAB III

Where was it discovered? 10 DAB III was initially discovered as a natural compound extracted from the Taxus baccata tree, primarily found in Europe and Asia.

Who discovered it? The discovery of 10 DAB III is attributed to researchers and scientists involved in the study of natural compounds and their potential pharmaceutical applications.

What is the story behind its discovery? The discovery of 10 DAB III marked a significant milestone in the pharmaceutical industry, offering a viable pathway for the synthesis of anti-cancer medications with improved efficiency and sustainability.

How did the product progress to come to its current state, what have been the major landmarks in its development? Over time, advancements in chemical synthesis and manufacturing technologies have facilitated the large-scale production of 10 DAB III, enabling pharmaceutical companies to meet the growing demand for anti-cancer drugs while minimizing environmental impact.

Exploring 10 DAB III and its Uses in Pharmaceuticals, Health, and Drug Industry

10 DAB III Uses and Properties

10 DAB III exhibits diverse pharmacological properties, primarily attributed to its role as a precursor in anti-cancer drug synthesis. Its unique molecular structure allows for efficient esterification, enhancing the bioavailability and therapeutic efficacy of Paclitaxel and Docitaxel. 

Additionally, 10 DAB III demonstrates potential applications in medicinal chemistry, facilitating the development of novel pharmaceutical formulations targeting various disease indications.

List of uses and their explanation:

  • Paclitaxel Synthesis: 10 DAB III serves as a crucial intermediate in the synthesis of Paclitaxel, a widely used chemotherapeutic agent for treating various types of cancer, including breast, lung, and ovarian cancer. The esterification process transforms 10 DAB III into Paclitaxel, enhancing its solubility and bioavailability for improved therapeutic outcomes.
  • Docitaxel Intermediate: Similarly, 10 DAB III acts as an essential intermediate in the production of Docitaxel, another potent anti-cancer medication used in the treatment of breast, prostate, and gastric cancers. Its incorporation into the synthesis process ensures the efficient conversion of precursor compounds into Docitaxel, maintaining pharmaceutical standards and efficacy.

Other additional properties:

  • Medicinal Chemistry Applications: Beyond its role in anti-cancer drug synthesis, 10 DAB III exhibits promising applications in medicinal chemistry research. Its chemical versatility and structural attributes enable researchers to explore new avenues in drug design and development, fostering innovation in pharmaceutical sciences.

The Raw Material from which 10 DAB III is extracted - Natural Source for 10 DAB III

Raw Material Overview

10 DAB III is extracted from the Taxus baccata tree, commonly known as the English yew or European yew. The tree’s leaves contain valuable phytochemical compounds, including 10 DAB III, which serves as a precursor to Paclitaxel and Docitaxel. 

HimPharm meticulously sources raw materials from sustainable yew tree populations, ensuring environmental sustainability and ethical harvesting practices.

Alternative Sources of Raw Material for Extracting 10 DAB III 

While Taxus baccata remains the primary source of 10 DAB III extraction, ongoing research explores alternative botanical sources and synthetic routes for obtaining this critical pharmaceutical intermediate. Alternative plant species and innovative extraction methodologies offer potential avenues for diversifying the supply chain and enhancing the sustainability of 10 DAB III production in the pharmaceutical industry.

HimPharm Manufacturing Standards

HimPharm’s Role in 10 DAB III Production

HimPharm stands as a pioneer in the production of 10 DAB III, leveraging decades of experience and expertise as a 10 DAB III manufacturer. Through stringent quality control measures and adherence to international regulatory standards, HimPharm ensures the consistent production of high-quality 10 DAB III, meeting the demands of global healthcare markets.

Upholding International Quality Standards

HimPharm places paramount importance on upholding international quality standards throughout the 10 DAB III manufacturing process. From raw material procurement to product formulation and quality assurance testing, every stage undergoes rigorous scrutiny to guarantee product integrity, purity, and efficacy. 

HimPharm’s commitment to excellence underscores its dedication to delivering pharmaceutical-grade 10 DAB III to its clientele worldwide.

HimPharm’s Commitment to Fulfilling Your Bulk Requirements for 10 DAB III

Empowered by state-of-the-art manufacturing facilities and scalable production capabilities, HimPharm caters to bulk requirements for 10 DAB III with unparalleled efficiency and reliability. 

Whether servicing the needs of multinational pharmaceutical companies or niche market segments, HimPharm remains committed to meeting client demands with precision and timeliness, reinforcing its reputation as a trusted supplier of pharmaceutical intermediates.

10 DAB III Production Processes

Details of the Step-by-Step Manufacturing Process of 10 DAB III

The manufacturing process of 10 DAB III involves several sequential steps, each carefully orchestrated to ensure product purity, potency, and consistency.

  • Raw Material Selection: High-quality Taxus baccata leaves serve as the primary raw material for 10 DAB III extraction. HimPharm meticulously selects leaves from sustainable sources, adhering to ethical harvesting practices to minimize environmental impact.
  • Extraction and Purification: The extraction process involves isolating 10 DAB III from Taxus baccata leaves using solvent-based techniques. Subsequent purification steps remove impurities and unwanted compounds, yielding a concentrated extract rich in 10 DAB III.
  • Chemical Modification (Esterification): Following purification, 10 DAB III undergoes chemical modification through esterification, a crucial step that enhances its pharmacological properties and compatibility with downstream drug synthesis processes.
  • Quality Control Testing: Throughout the manufacturing process, rigorous quality control testing is conducted to assess the purity, potency, and safety of 10 DAB III. Analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry ensure adherence to pharmacopoeial standards and regulatory requirements.

Testing in 10 DAB III Manufacturing

Quality assurance is paramount in 10 DAB III manufacturing, with comprehensive testing protocols employed to verify product integrity and compliance with regulatory standards.

  • Identity Testing: Authenticity and botanical identity of the raw material are confirmed through macroscopic and microscopic examination, ensuring consistency and traceability throughout the production chain.
  • Purity Analysis: Chemical analysis techniques determine the purity of 10 DAB III extract, quantifying impurities and contaminants to meet pharmacopoeial specifications and industry standards.
  • Potency Assay: Quantitative assays assess the concentration of 10 DAB III and related compounds, ensuring consistency and potency across production batches for reliable drug synthesis.
  • Microbiological Testing: Microbial screening safeguards product safety and sterility, mitigating the risk of contamination and ensuring compliance with regulatory requirements.
  • Stability Testing: Stability studies evaluate the shelf-life and storage conditions of 10 DAB III, assessing its physical and chemical properties over time to maintain product efficacy and integrity.

Navigating Production Bottlenecks in 10 DAB III Manufacturing

The dynamic nature of pharmaceutical manufacturing poses inherent challenges and bottlenecks that require proactive management and strategic solutions.

  • Raw Material Sourcing: Ensuring a consistent and sustainable supply of Taxus baccata leaves is essential to mitigate raw material shortages and maintain production continuity. HimPharm collaborates with trusted suppliers and implements inventory management strategies to optimize raw material procurement and storage.
  • Process Optimization: Continuous process improvement initiatives enhance manufacturing efficiency and throughput, minimizing production downtime and maximizing resource utilization. HimPharm employs lean manufacturing principles and advanced technologies to streamline operations and eliminate inefficiencies.
  • Regulatory Compliance: Adhering to evolving regulatory requirements and pharmacopoeial standards demands proactive vigilance and compliance management. HimPharm remains abreast of regulatory updates and invests in training and infrastructure to ensure adherence to industry best practices and legal obligations.
  • Supply Chain Logistics: Efficient logistics and distribution networks are critical to ensuring timely delivery of 10 DAB III to customers worldwide. HimPharm leverages strategic partnerships and logistics expertise to optimize supply chain operations and minimize lead times, enhancing customer satisfaction and market competitiveness.

HimPharm’s Manufacturing Advantage

HimPharm’s manufacturing advantage lies in its unwavering commitment to excellence, innovation, and customer satisfaction. By embracing cutting-edge technologies and best-in-class manufacturing practices, HimPharm delivers pharmaceutical-grade 10 DAB III of exceptional quality and reliability. 

Through continuous improvement and customer-centricity, HimPharm remains a trusted partner in the global pharmaceutical industry, driving innovation and advancing healthcare solutions for a better tomorrow.

Conclusion

In conclusion, the synthesis and production of 10 DAB III represent a pivotal advancement in the pharmaceutical industry, particularly in anti-cancer drug development. This phytochemical serves as a critical precursor for the synthesis of potent anti-cancer medications such as Paclitaxel and Docitaxel, offering sustainable and efficient alternatives to traditional extraction methods.

HimPharm, as a leading pharmaceutical manufacturer, upholds stringent quality standards and manufacturing practices, ensuring the integrity and purity of 10 DAB III. Through its unwavering commitment to excellence and innovation, HimPharm stands as a beacon of reliability and trust in the pharmaceutical landscape. 

By leveraging HimPharm’s manufacturing capabilities and adherence to international quality standards, pharmaceutical companies, healthcare institutions, and drug manufacturers can access top-quality 10 DAB III for their production needs. HimPharm’s modern facilities and extensive experience enable the seamless scaling of production, accommodating both bulk requirements and niche market demands.

Leveraging HimPharm’s Commitment to Quality and its manufacturing facility to fulfill your demand for top quality 10 DAB III requirements

At HimPharm, we understand the critical importance of sourcing high-quality 10 DAB III for pharmaceutical formulations and drug development. With over four decades of experience and a legacy of excellence, HimPharm stands as a trusted partner in the global pharmaceutical industry.

Our state-of-the-art manufacturing facility is equipped to meet the most stringent quality standards and regulatory requirements, ensuring the purity, potency, and safety of every batch of 10 DAB III. From raw material procurement to product formulation, we adhere to best-in-class practices and quality assurance protocols, delivering pharmaceutical-grade 10 DAB III that exceeds industry benchmarks.

Whether you require bulk quantities or specialized formulations, HimPharm offers customized solutions tailored to your specific needs. Our commitment to quality, reliability, and customer satisfaction sets us apart as a preferred supplier of 10 DAB III for pharmaceutical companies, drug manufacturers, and healthcare institutions worldwide.

Partner with HimPharm and experience the difference in pharmaceutical excellence. Contact us today to discuss your 10 DAB III requirements and discover how we can support your journey towards better healthcare outcomes.

Write to or Call HimPharm to Request a Quote, COA, and MSDS.

for

10-Deacetyl Baccatin III (10 DAB III) USP
Follow us around the web

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

©

2024

HimPharm.com. All Rights Reserved.